Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

AcrySof® IQ toric IOL for astigmatism correction in cataract surgery

Poster Details

First Author: S. Galvez-Carvajal SPAIN

Co Author(s):    R. Luchena-Lopez   F. Ramirez-Lopez   A. Alfaro-Juarez              

Abstract Details

Purpose:

To evaluate the refractive outcomes and rotational stability of the Acrysof® IQ Toric IOL for the correction of preexisting corneal astigmatism in patients undergoing routine cataract surgery.

Setting:

Patients with cataract and corneal astigmatism > 1,0 diopters (D) were included in this prospective study.

Methods:

Pentacam HR (Oculus) was performed in all patients preoperatively and the cornea was marked in the sitting position with a pendulum marker. The minimun follow-up was 1 month. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), residual refractive sphere, residual keratometric and refractive cylinders, and toric IOL axis were measured before and 1 day, 1 week, and 1 month after surgery. IOL misalignment and rotational stability were assessed by retroillumination photographs.

Results:

Fourteen eyes of 8 patients were included in this study. The mean pre-operative corneal astigmatism was 3,44D. The mean cylinder reduction was approximately 70% with a mean post-operative refractive cylinder of 1,1D. The mean post- operative UDVA was 0,68. Mean IOL rotation was 3,5 degrees with all eyes with an IOL rotation inferior to 10 degrees. No complications were observed.

Conclusions:

Implantation of the Acrysof® IQ Toric is a safe and effective method to correct corneal astigmatism in patients undergoing routine cataract surgery. The IOL showed a good rotational stability.

Financial Disclosure:

NONE

Back to Poster listing